Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$0.00$0.00no prior Q1 2019 on file Net Income-$4.23M-$4.23MN/M vs Q1 2019 EPS Diluted-$0.97-$0.97N/M vs Q1 2019 Operating Income-$4,186,937N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,677,962N/M ended Mar 31, 2020 · filed Jun 29, 2020 · 90 d after period end